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Cutaneous cancers represent a major public health con-
cern due to the very high incidence, associated medical
costs, substantial mortality, and cosmetic deformities
associated with treatment. Considerable progress in ba-
sic research has provided new insights into the underly-
ing genetic basis of the major human cutaneous
cancers, malignant melanoma, basal cell carcinoma,
and squamous cell carcinoma. In turn, these genetic in-
sights have illuminated biochemical pathways that pro-
mise to provide new approaches to the prevention and
treatment of cutaneous neoplasms. This review will de-
tail the evolving genetic information and indicate how
this information is being used to re¢ne experimental
models that serve to both de¢ne the biochemistry of
cancer pathogenesis and test novel approaches to cancer
therapy. Combined with preventive measures to reduce
exposure to sunlight, these advances are likely to reduce
this major public health burden in the coming decade.
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P
erhaps no other dermatologic condition dominates a
major area of human pathology as does cutaneous
cancer. More than half of all cancers in North America
occur on the skin, and this is likely to be an underesti-
mate.This year more than 1million nonmelanoma skin
cancers will be reported in the U.S.A. Although the mortality
from these cancers is relatively low, the magnitude of the inci-
dence is so great that mortality from nonmelanoma skin cancers
equals that of Hodgkin’s disease and uterine cancer. Furthermore,
the health care costs, morbidity, and cosmetic defects resulting
from current treatments make nonmelanoma skin cancers a major
public health issue. The statistics for melanomas are even more
discouraging.This tumor type is displaying the second largest in-
crease in incidence among cancers in the American population,
with over 50,000 cases expected in 2001 and a 7% mortality rate.
As exposure to sunlight is the primary etiologic agent for all skin
cancers, ultraviolet (UV) radiation must be considered the major
carcinogen in the human environment. Ultraviolet radiation is a
powerful carcinogenic stimulus by virtue of its ability to damage
DNA and cause mutations, its capacity to activate signaling path-
ways that enhance selection of incipient neoplastic cells, and its
activity as an immune suppressant (De Gruijl, 1999). Skin cancer
prevention therefore should be achievable through education and
lifestyle modi¢cations that reduce exposure to UV radiation.
Although both government agencies and dermatologic societies
have instituted approaches to educate the population on the dan-
gers of sunlight exposure, societal experience indicates that such
programs will have only limited success. Thus, the need for basic
and applied research into the causes and potential nondeforming
therapies for cutaneous cancers has never been more urgent.
Although sun exposure is a major etiologic component of most
skin cancers, other exogenous exposures also contribute to this
epidemic of human neoplasia. As shown in Table I, lifestyle fac-
tors such as smoking and diet, occupational exposures, and certain
topical or systemic medicinal therapies contribute to the overall
incidence of both melanoma and nonmelanoma cancers (Black et
al, 1994; Gallagher et al, 1996; De Hertog et al, 2001). Arsenic expo-
sure, through occupational or environmental contact, also may
contribute to the rising skin cancer rate (Schwartz, 1997).
HEREDITARYCANCER SYNDROMES
Considerable insight into the genetic basis of sporadic skin can-
cers has come from the elucidation of speci¢c genes or genetic
loci that de¢ne hereditary skin tumor syndromes (Table II)
(Halpern and Altman, 1999). Perhaps the best de¢ned and most
broadly relevant are the DNA repair genes that comprise the
complementation groups of skin cancer prone xeroderma pig-
mentosum families (van Steeg and Kraemer, 1999). At least
six independent genes, on distinct chromosomal loci, de¢ne pro-
teins involved in nucleotide excision repair. Among these are
proteins that recognize and bind to sites of DNA damage (XPA,
XPC), helicases (XPB, XPD), and endonuclease components
(XPG, XPF), defects in any of which give a skin cancer prone
phenotype. Potential polymorphisms with functional conse-
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quences in these and other DNA repair genes may contribute to
susceptibility states in the general population as well (Wei et al,
1994). Chromosomal mapping studies in the basal cell nevus syn-
drome, coupled with genetic and functional studies of Drosophila
development, revealed the Sonic hedgehog pathway, and speci¢-
cally mutations in the PTCH1 gene, as the basis for hereditary
and many sporadic basal cell cancers (Bale andYu, 2001). Likewise
the mapping of the inheritance pattern of the dysplastic nevus
syndrome focused attention on the INK4a locus and speci¢cally
mutations in the p16INK4a gene in the etiology of heredity-prone
and sporadic melanoma (Hussussian et al, 1994). Subsequently, de-
fects in p16INK4a or other components of the cyclin-CDK signal-
ing pathway have been associated with both melanoma and
nonmelanoma skin cancer (Sou¢r et al, 1999). Detection of speci-
¢c mutations in Cowden’s syndrome (PTEN), Muir^Torre syn-
drome (MSH2, MLH1), pilomatricoma (CTNNB [b-catenin]),
and trichoepithelioma (PTCH1, p16INK4aA) has illuminated the
underlying pathways associated with adnexal tumors. The deli-
neation of the speci¢c genes mutated in other syndromes where
locus mapping is con¢rmed should reveal even more insight into
the broader spectrum of skin neoplasms.
CUTANEOUS MALIGNANTMELANOMA
Etiology and genetics Cutaneous malignant melanoma
(CMM) typically presents as a pigmented lesion that evolves
either from a pre-existing nevus or arises de novo in normal-
appearing skin. Compared with benign nevi, CMM frequently
exhibit one or more of the following features (the ABCD of
melanoma): asymmetry, border irregularity, color variegation,
and diameter greater than 6mm. CMM is notorious for its
highly aggressive nature and its resistance to currently existing
radiation and chemotherapeutic modalities. In fact, no standard
therapy exists for patients with disseminated melanoma, who
have a dismal prognosis. Recently, this potentially fatal disease
has exhibited an alarming increase in incidence (Rigel et al,
1996), evolving into a considerable health crisis. Epidemiologic
evidence now points to a causal role for exposure to the UV
spectrum of sunlight in the etiology of CMM (IARC, 1992;
Armstrong and Kricker, 1995), although the relative
contributions of UVA (320^400 nm) and UVB (280^320 nm)
are still disputed. Whereas UVA is thought to incite oxidative
DNA damage, UVB can suppress cell-mediated immunity and
induce the formation of characteristic pyrimidine dimers (De
Gruijl, 2000). Notably, unlike the more common squamous cell
carcinoma (SCC), which is associated with cumulative lifetime
UV exposure, melanoma appears to be induced by intense,
intermittent exposure to UV, particularly during childhood
(Holman et al, 1983; Whiteman et al, 2001). In addition to sun
exposure, other strong melanoma risk factors include the total
number of nevi and dysplastic nevi, skin and hair color, and
germline mutations in speci¢c tumor suppressor genes
(Goldstein and Tucker, 1993; Marks, 2000).
Table I. Environmental agents associated with the development of human skin cancera
Agent Individual at risk Route of exposure Tumor types
UVA/UVB (sunlight) All T AK, BD, SCC, BCC, M
Cigarette smoke Smokers T or S SCC, BCC
Soot Chimney sweep T SCC
Coat tar, pitch Coker of coal, steel worker T SCC
Petroleum oils Machinest, textile worker T and S SCC
Arsenic Agriculture worker, etc. S and/or T BD, SCC, BCC
4,40 -Bipridyl Pesticide manufacturer T SCC, BD
PCB Petrochemical worker T or S M
Dry cleaning reagents Dry cleaners T or S BCC
Fiberglass Insulators T BCC
Psoralen (PUVA) Psoriasis patient T and S SCC, BCC, M
Nitrogen mustard CTCL patient T SCC
Immunosuppressants Transplant recipients, etc S SCC, BCC
Therapeutic x-ray Cutaneous infections T BCC
aT, topical; S, systemic; SCC, squamous cell carcinoma; BD, Bowen’s disease; BCC, basal cell carcinoma; AK, actinic keratosis; PCB, polychlorinated biphenyl;
M, melanoma, CTCL, cutaneous T-cell lymphoma.
Table II. Gene targets for mutations in hereditary and sporadic cutaneous cancers
Gene Function Locus Tumor type Syndrome Spontaneous
p53 DNA repair, apoptosis, 17 p13.1 BCC, SCC Li Fraumeni (but no yes
cell cycle regulation increase in skin cancers)
XPA, XPB DNA repair 3p25, 2q21 BCC, SCC, melanoma xeroderma pigmentosum possible
XPC, XPD 9q22.3, 19q13.3
XPF, XPG 16p13.3-13, 13q22
PTCH1 Sonic hedgehog receptor 9q22.3 BCC, trichoepithelioma nevoid basal cell carcinoma yes
SMO Sonic hedgehog e¡ector 7q31-32 BCC ? yes
p16INK4a cyclin inhibitor 9p21 melanoma, SCC, trichoepithelioma dysplastic nevus yes
BRAF kinase 7q34 melanoma ? yes
CTNNB (b-catenin) cell^cell adhesion, 3p22-p21.3 pilomatricoma ? yes
transcription factor
CYLD1 unknown 16q12-13 cylindroma multiple cylindroma yes
PTEN phosphatase 10q23.3 trichilemmoma Cowden’s unknown
MSH2 mismatch repair 2p22-p21 sebaceous gland carcinoma Muir-Torre unknown
MLH1 3p21.3
? ? 9p21 trichoepithelioma multiple trichoepithelioma unknown
? ? Xq24-q27 BCC Bazex unknown
? ? 9q31 keratoacanthoma Ferguson-Smith unknown
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Cytogenetic, linkage, and molecular analyses have provided
compelling evidence for a strong underlying genetic basis for
the genesis and progression of CMM (Chin et al, 1998) (Fig 1).
With few exceptions, however, these same studies have failed to
identify consistent melanoma-associated genetic alterations. One
signi¢cant exception is the INK4a locus at 9p21, which encodes
in alternative reading frames two distinct tumor suppressor genes,
p16INK4a and p19ARF (Quelle et al, 1995). Germline mutations in
the p16INK4a gene, a negative regulator of the cell cycle, and
subsequent loss of heterozygosity (LOH) in arising melanoma,
are frequently observed in CMM-prone kindreds (Hussussian
et al, 1994; Kamb et al, 1994; FitzGerald et al, 1996). In sporadic
CMM, INK4a mutations are less frequent, but functional loss
of p16INK4a in tumors can also occur through epigenetic
mechanisms, such as promoter hypermethylation (Gonzalgo
et al, 1997; Funk et al, 1998). The signi¢cance of the pRB
pathway, of which p16INK4a is a major regulator in
melanomagenesis, can be gleaned from the identi¢cation of
germline mutations in two additional melanoma-prone kindreds
of cyclin-dependent kinase 4 (CDK4), a promoter of cell cycle
progression and a target of p16INK4a inhibition (Zuo et al, 1996;
Russo et al, 1998; Sou¢r et al, 1998). Interestingly, p53, situated at
the regulatory nexus of cellular growth and apoptosis, and the
most common mutational target in human cancer (Cariello et al,
1994), is infrequently mutated in primary melanoma (Zerp et al,
1999; Bardeesy et al, 2001;and references within). It has been
postulated that this rarity can be at least partially accounted for
by the positioning of p19ARF, often inactivated in melanoma as a
component of the INK4a locus, upstream of p53 (Chin et al,
1998). Such a con¢guration would render inactivating mutations
in both genes redundant with respect to cell cycle regulation.
A second exception where speci¢c genetic alterations have
been clearly associated with CMM is in the MAPK signaling
pathway. Although activating mutations in members of the RAS
proto-oncogene family are among the most common in human
cancer, demonstrating a causal role in CMM has proven elusive;
however, more recent molecular analysis of primary and
metastatic melanoma has implicated N-RAS and H-RAS
mutations in CMM progression (Chin et al, 1997). More
signi¢cantly, a recent report has identi¢ed activating mutations
in BRAF, which acts downstream of Ras, in almost 70% of
human CMM (Davies et al, 2002).
Point mutations with characteristic UV-associated signatures
have been found in genes situated within those molecular
pathways described above, including p16INK4a (Kamb et al, 1994;
Pollock et al, 1995), N-RAS (van’t Veer et al, 1989; van Elsas et al,
1997; Jiveskog et al, 1998), and p53 (Zerp et al, 1999), but not ARF
(Peris et al, 1999). These ¢ndings suggest that such critical genes
can be the target of both hereditary and environmental insults.
Recent epidemiologic data indicate that INK4a-associated
melanoma-prone kindreds in geographic areas with the greatest
exposure to sunlight are also at highest risk for melanoma,
linking UV irradiation to the INK4a locus (Bishop et al, 2002).
Therefore, assessing the consequences of exposure to combina-
tions of such risk factors represents an area of great experimental
opportunity; however, at this time functional relationships
between candidate genes and environmental factors in
melanomagenesis are largely unknown.
Other classes of molecules have been implicated in melano-
magenesis as well. Receptor tyrosine kinases (RTK), critical
modulators of virtually all fundamental cellular behavior,
including growth, di¡erentiation, motility, and survival, play
signi¢cant roles in normal melanocyte development and
function (Bennett, 1993; Halaban, 1996). These include c-Kit
(Witte, 1990), c-Met (Halaban et al, 1992; Takayama et al, 1996;
Kos et al, 1999), and the platelet-derived growth factor receptor
(Stephenson et al, 1991; Soriano, 1997). Multiple reports have
either supported or refuted the role of speci¢c RTK in primary
and metastatic melanoma cells and their cultured derivatives
(Albino, 1992; Shih and Herlyn, 1994; Halaban, 1996). Of central
importance to the aspiring melanoma cell is the acquisition of
autonomous growth control through the creation of autocrine
RTK signaling loops, i.e., a cell is able to manufacture both an
RTK and its associated ligand. Examples of such loops include
basic ¢broblast growth factor (bFGF)-FGF receptor, considered a
hallmark of CMM development, and transforming growth factor
a (TGFa)-epidermal growth factor (EGF) receptor.
Recently, progress has been made in identifying new candidate
therapeutic targets associated with melanoma cell survival.
Soengas et al (2001) demonstrated that melanoma cells avoid
apoptotic destruction through inactivation of apoptotic protease
activating factor-1 (APAF-1), a requisite caspase-9 activator
functioning downstream of p53. Common APAF-1 loss of
function, which can occur by allelic loss and methylation
silencing, also helps account for the relative rarity of p53
mutations in CMM. Signi¢cantly, restoration of APAF-1
pro-apoptotic function by the methylation inhibitor 5aza2dC
rendered melanoma cells chemosensitive (Soengas et al, 2001). In
a related development, Gri⁄th et al (2000) showed that
adenovirus-mediated expression of TNF-related apoptosis-
inducing ligand (TRAIL), which induces caspase-8-associated
apoptosis, can serve as gene therapy in the destruction of
melanoma cells.
Experimental models of CMM A major impediment to the
study of melanoma has been the lack of relevant, tractable
experimental animal models. Historically, the animal models
studied in most detail have been the Xiphophorus hybrid ¢sh and
the South American opossum, as well as a number of rodent
models (Kusewitt and Ley, 1996) (Table III). The problem with
all such models, however, is that arising melanocytic tumors do
not resemble human CMM at the histopathologic level, and
extensive genetic manipulation is not possible. The mouse
represents an especially attractive system because of the
availability of an extensive genetic base upon which to build.
Unfortunately, murine melanocytes, unlike those in human
skin, are typically con¢ned to hair follicles and are exceedingly
resistant to both spontaneous and UV-induced melanoma.
Moreover, melanomas that arise do so with low penetrance,
long latencies, and poor metastatic capacity.
Genetically engineered mouse models have proven to be
amenable to the genetic dissection of molecular pathways in
tumorigenesis, and a number of melanoma-prone, transgenic
mice have recently been described (Satyamoorthy et al, 1999;
Tietze and Chin, 2000). Among these, melanoma induction in
transgenic mice has been achieved through melanocytic
expression of the oncogenes SV40 T-antigen, c-RET and H-
RAS (Bradl et al, 1991; Klein-Szanto et al, 1994; Kato et al, 1998;
Bardeesy et al, 2001). The success of these models can be credited,
in part, to earlier seminal work identifying candidate oncogenic
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Figure1. Genetic changes associated with melanoma progression.
The multistage evolution of metastatic melanoma is depicted schematically
with frequently associated stage-speci¢c genetic changes detailed below.
Trisomy of 7q, detected in invasive vertical growth phase melanoma,
would amplify the listed tyrosine kinase receptors (EGFR, c-MET) the li-
gand HGF, and BRAF, but a causal relation to progression is not proven.
The loss of APAF-1 may occur through gene deletion or gene silencing.
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pathways in human CMM: T-antigen disrupts pRB and p53
function in a fashion analogous to loss of both p16INK4a and
p19ARF at the INK4a locus; c-RET, although not normally
expressed in melanocytes, is a potent RTK whose presence
would unbalance multiple kinase signaling pathways; and the
potential role of activated RAS genes has already been noted. In
an elegant set of genetic experiments, the activated H-RAS
transgene was placed on a background de¢cient in Ink4a
resulting in the e⁄cient development of spontaneous
nonmetastatic melanoma (Chin et al, 1997). Moreover, when the
H-RAS transgene was con¢gured with a tetracycline-regulatable
promoter, it could be demonstrated that activated H-RAS was
required for melanoma maintenance in this model (Chin et al,
1999). Recently, mice bearing p16Ink4a-speci¢c inactivating
mutations, or the Cdk4 R24C mutation described in patients
with familial CMM, were reported to be susceptible to DMBA-
induced melanoma (Krimpenfort et al, 2001; Sharpless et al, 2001;
Sotillo et al, 2001; Rane et al, 2002), strongly supporting a role for
the p16INK4a/Cdk4/Rb pathway in melanomagenesis. As in other
animal models, however, murine melanocytic neoplasms arising
in these various transgenic mice do not closely resemble human
lesions, in that they arise within the dermis and lack the
epidermal component characteristic of conventional human
CMM.
In melanoma-prone transgenic mice overexpressing hepatocyte
growth factor/scatter factor (HGF/SF), the c-Met ligand,
metastasis occurs in approximately 15% of tumor-bearing
animals (Takayama et al, 1996; 1997; Otsuka et al, 1998). Unlike
other genetically engineered animals, melanocytes in HGF/SF
transgenic mice demonstrate extra-follicular survival, residing
within the epidermis, dermis, and epidermal^dermal junction.
The resulting ‘‘humanized’’ skin has the potential to yield
melanomas with a histopathologic pro¢le reminiscent of human
CMM (Noonan et al, 2001). As an alternative to making mouse
skin morphologically resemble human, human/mouse chimeras
have been created in which human skin is grafted onto
immunode¢cient mice, and then subjected to experimental
analysis (Satyamoorthy et al, 1999). Such chimeras provide an
orthotopic milieu in which to study spontaneous and UV-
induced melanomagenesis in vivo. In fact, UVB exposure was
capable of inducing melanocytic lesions, including a nodular
melanoma, in xenografted human skin in concert with either
DMBA treatment or adenovirus-mediated bFGF overexpression
(Atillasoy et al, 1998; Berking et al, 2001).
The ability to evaluate the consequences of UV irradiation on
melanoma development is a paramount feature in any animal
model, as exposure to sunlight is thought to be a causal agent in
up to 80% of CMM. With respect to genetically tractable
transgenic mouse models of melanoma, some demonstrate UV
sensitivity, although responses have been relatively ine⁄cient
(Kelsall and Mintz, 1998; Broome et al, 1999). The extra-follicular
melanocytes in the HGF/SF transgenic skin, however, appear to
be highly susceptible to neonatal UV irradiation (Noonan et al,
2000; 2001), linking both the power of genetic manipulation and
the relevance of environmental challenge within the same model
system. Taken together, these advances brighten future prospects
of creating relevant mouse models to rigorously assess genetic and
environmental melanoma risk factors, facilitate development
of e⁄cacious sun protection strategies, and establish e¡ectual
antimelanoma therapeutics.
BASAL CELL CARCINOMA (BCC)
Etiology and genetics BCC is a very common, slow-growing,
locally invasive tumor that typically presents as a pink or pearly
papule with super¢cial telangiectasia and occasional ulceration.
There are three clinical variants: nodular (the most common),
super¢cial, and sclerosing. In contrast to cutaneous SCC, BCC
precursor lesions have not been identi¢ed, there is no evidence
of neoplastic progression, and metastases are exceedingly rare
(Miller, 1995). BCC are probably derived from hair follicles, and
analogous to hair follicle epithelium, BCC growth is dependent
on proper signaling between neoplastic keratinocytes and
surrounding mesenchymal cells. This may account, in part, for
the low incidence of BCC metastases, as well as the di⁄culty in
establishing and maintaining BCC as xenografts in vivo or as
immortalized cell lines in vitro.
Chromosomal losses involving 9q have been found in both
sporadic and inherited BCC. The latter tumors occur in patients
with the autosomal dominant disorder nevoid basal cell
carcinoma syndrome (NBCCS), which is characterized by a
predisposition to BCC (frequently multiple and appearing at an
early age), an increased incidence of several other tumors, and a
Table III. Experimental models for melanoma induction
Exogenous inducers
Agent Species Comments
DMBA/TPA Syrian golden hamster requires transplantation
DMBA guinea pig frequent metastasis
UVR (280-400 nm) monodelphus domestica 100 week exposure
DMBA/UVR human skin grafted to nude mice carcinoma and melanoma after repeated exposure
Heritable models
Species Enhanders Comments
Xiphorphorus UVR overexpression of RTK-ONC-Xmrk
Sinclair swine 2 loci often regress with vitiligo
Genetic modi¢ed mouse models
Modi¢cations Enhanders Comments
Tyr-Tag UVR mostly ocular, cutaneous requires UVR
TP-ras UVR or DMBA required metastatic
MT-RET melanosis; metastatic
MT-HGF UVR melanosis; metastatic
Tyr-RAS INK4a/, p53/ non-metastatic
Ink4an/ARF D2,3 DMBA metastatic
Cdk4þ / R24C DMBA and TPA knock in mutant; invasive
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variety of developmental anomalies (Gorlin, 1987). These clinical
features suggested that the gene involved in BCC formation is
also important during embryogenesis, and this notion was
con¢rmed with the discovery in NBCCS patients of germline
mutations of PTCH1 (Hahn et al, 1996; Johnson et al, 1996), a
homolog of the Drosophila ptc gene involved in embryonic
development. BCC from NBCCS patients had lost the
remaining normal PTCH1 allele, which was also found to be
de¢cient in spontaneous BCC, suggesting that PTCH1 is a
tumor suppressor. A second PTCH gene has subsequently been
identi¢ed (PTCH2) (Zaphiropoulos et al, 1999), but its role in
BCC development is not yet known.
Ptch1 is a 12-pass transmembrane molecule that functions as a
receptor for Sonic hedgehog (Shh), a secreted ligand that
regulates proliferation and patterning of multiple tissues and
organs during embryogenesis (Chuang and Kornberg, 2000).
According to the current model (Fig 2), Ptch1 normally
antagonizes signaling activity by repressing Smoothened (Smo),
a cell-surface molecule with homology to G protein-coupled
receptors. Shh initiates signaling in responsive cell types by
inhibiting Ptch, resulting in derepression of Smo and,
ultimately, the activation of Shh target genes. Two ‘‘universal’’
Shh target genes are Gli1 (which encodes a transcription factor)
and Ptch1, and the expression level of these transcripts has
proven to be a reliable indicator of physiologic and pathologic
Shh signaling. Under normal conditions, activation of this
pathway is dependent on Shh, whose expression is tightly
regulated both in space and in time. In human BCC, however,
loss of PTCH1 results in constitutive signaling that is irreversible
and independent of SHH. In addition to loss-of-function PTCH1
mutations, gain-of-function (oncogenic) SMO mutations have
been found in some BCC where PTCH1 appears to be normal
(Xie et al, 1998; Lam et al, 1999). Together, PTCH1 or SMO
mutations have been identi¢ed in less than 75% of BCC
whereas hedgehog target genes are upregulated in essentially all
tumors examined (Dahmane et al, 1997), indicating that
additional mechanisms must exist for uncontrolled activation of
this pathway. The current data suggest that constitutive Shh
signaling, regardless of how this is brought about, plays a central
role in the genesis of BCC. PTCH1 gene alterations have also
been found in trichoepitheliomas (Vorechovsky et al, 1997) and
nevus sebaceous of Jadassohn (Xin et al, 1999), suggesting that
deregulation of Shh signaling plays a role in the genesis of other
follicle-derived tumors. Although mutations in p53 have been
found in up to 50% of BCC, their involvement in the
development or maintenance of these tumors is not known,
particularly as most BCC fail to exhibit the genomic instability
associated with other cancers where p53 function is
compromised.
What is the normal function of Shh signaling in skin? Analysis
of genetically engineered mutant mice has revealed a crucial
requirement for Shh during hair follicle growth and
morphogenesis, but not terminal di¡erentiation (St Jacques et al,
1998; Chiang et al, 1999). In addition, both loss-of-function
(Wang et al, 2000) and gain-of-function (Sato et al, 1999) studies
implicate Shh signaling in the regulation of hair follicle growth
during the anagen phase of the hair cycle. Thus, whereas
physiologic Shh signaling in skin may govern growth of follicle
keratinocytes at appropriate times, uncontrolled Shh signaling
due to PTCH1 or SMO mutations may cause sustained
proliferation, resulting in the development of follicle-derived
tumors.
How does stimulation of Shh signaling alter cell function?
Transcriptional responses in the highly homologous Drosophila
hedgehog pathway are mediated by ci (reviewed in Aza-Blanc and
Kornberg, 1999), which belongs to the Gli family of zinc ¢nger-
containing transcription factors. Vertebrate ci homologs include
Gli1, Gli2, and Gli3, all of which bind to the consensus DNA
sequence GACCACCCA (Matize and Joyner, 1999). In contrast
to Gli3, which appears to function primarily as a transcriptional
repressor, both Gli1 and Gli2 are transcriptional activators. Major
emphasis has been placed on Gli1 as a potential e¡ector of normal
and constitutive Shh signaling for several reasons: it is
consistently upregulated in cells where the Shh pathway is
active, both during embryogenesis and in neoplasms; ectopic
Gli1 expression can mimic responses to Shh in certain settings;
and when overexpressed in frog skin, GLI1 can give rise to
primitive skin tumors (Dahmane et al, 1997). Despite these
¢ndings Gli1 knockout mice are phenotypically normal (Morris
and Potten, 1999), arguing against an essential role for this Gli
protein in physiologic Shh signaling, whereas Gli2 knockout
mice exhibit abnormalities in multiple organs whose
development is dependent on Shh. In particular, loss of Gli2
function results in severe impairment of hair follicle growth
(Grachtchouk et al, 2000a).
Experimental models of BCC Rats exposed to chemical
carcinogens (MCA, DMBA) or ionizing radiation preferentially
develop BCC rather than squamous tumors, and frequently at a
high incidence (reviewed in Zackheim, 1985;Table IV). Rat BCC
appear to arise in the outer root sheath of hair follicles and have a
slow growth rate, similar to human BCC.The molecular basis for
experimentally induced BCC in rats is not yet known, but is
expected to result in Shh pathway activation if the current
model is accurate. In striking contrast to their strong
predisposition to squamous tumor development, mice appear to
be remarkably resistant to BCC induction. One notable
exception is the chemical carcinogen dehydroretronecine, which
is e¡ective at inducing mouse BCC (and other tumors) following
subcutaneous or topical administration (Johnson et al, 1978).
The discovery of inactivating PTCH1 mutations in BCC
fueled the development of a number of transgenic and knockout
mouse models exploring the potential role of deregulated Shh
signaling in BCC tumorigenesis. Overexpression of SHH using
a K14 promoter resulted in upregulation of Shh target genes and
development of basal cell-like proliferations in newborn mouse
skin (Oro et al, 1997), with similar results obtained using the K5
promoter to drive expression of a gain-of-function SMOmutant,
M2SMO (Xie et al, 1998). Overexpression of SHH in human
keratinocytes followed by grafting onto SCID mice resulted in
development of BCC-like changes as well (Fan et al, 1997). These
studies supported the hypothesis that constitutive activation of
Shh signaling in keratinocytes is su⁄cient for BCC
development, but analysis of tumor phenotypes in adult
transgenic mice could not be performed due to impaired
viability of these animals. When K14-SHH mouse skin was
transplanted onto SCID mouse hosts, BCC-like proliferations
were apparently replaced by well-di¡erentiated hair-follicle-like
structures (Oro et al, 1997), supporting the proposed requirement
for an appropriate tumor stroma to maintain BCC growth.
Mouse models have also been developed in which Ptch gene
PTCH1 SMO
repressed
SHH
 PTCH1
repressed SMOactive
SMO
active
X
SHH
GLI1,2GLI1,2
PTCH1 SMO
active
GLI1,2
Resting State
Physiologic Activation
in Hair Follicles
(Reversible)
Pathologic Activation
in BCC (Irreversible)
PTCH1
loss-of-function
SMO
gain-of-function
or
Figure 2. Proposed model depicting the molecular basis of BCC. In
contrast to the multistep evolution of SCC and melanoma, deregulation of
the SHH signaling pathway may be su⁄cient for BCC development. Dur-
ing physiologic activation in responsive cell types, SHH binds and inhibits
PTCH1, which normally represses SMO. Derepression of SMO results in
transient activation of SHH target genes, including PTCH1, GLI1, and cell
type-speci¢c genes, which are likely to play an important role in growth
control. In BCC, mutations involving PTCH1 or SMO result in uncon-
trolled signaling and constitutive expression of SHH target genes.
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function has been disrupted (Goodrich et al, 1997; Hahn et al,
1998), and Ptchþ /^ mice have many features in common with
NBCCS patients. Detailed analysis of skin from PtchlacZ/þ mice
has revealed microscopic hair-follicle-derived proliferations, with
the appearance of a variety of macroscopic skin tumors, including
BCC, following exposure to ionizing or UV radiation
(Aszterbaum et al, 1999). Taken together, these ¢ndings strongly
support the concept that deregulated Shh signaling plays a
central role in BCC development.
Other transgenic mouse studies have focused on Gli proteins as
potential mediators of constitutively activated Shh signaling in
BCC. GLI1 and Gli2 have both been overexpressed in mouse
skin using the same bovine K5 promoter with intriguingly
di¡erent results. K5-GLI1 transgenic mice developed a variety of
follicle-derived tumor types with relatively few BCC (Nilsson et
al 2000), whereas K5-Gli2 transgenic mice developed only BCC
(Grachtchouk et al 2000b). These ¢ndings, coupled with the
results of knockout mouse studies described above, strongly
implicate Gli2 both in physiologic (hair follicle growth) and
pathologic (BCC development) Shh signaling in skin. Despite
the compelling phenotypes produced in these mouse models,
there is as yet no direct evidence that Gli transcription factors
are required for tumorigenesis associated with PTCH1 or SMO
mutations.
As it appears that deregulation of Shh signaling is su⁄cient for
BCC development, these tumors may be uniquely responsive to
mechanism-based therapeutic intervention. The steroidal alkaloid
cyclopamine has been shown to inhibit Shh signaling by
blocking SMO (Taipale et al, 2000), but it is not yet known
whether BCC could be successfully treated, or their appearance
prevented, using this agent. In September 2001, one small-
molecule inhibitor of Shh signaling had been granted FDA
approval for phase I clinical trials in patients with BCC.
Although this type of work is just getting under way, it may
eventually lead to novel nonsurgical approaches to treating BCC
and possibly other cancers associated with deregulated Shh
signaling, such as medulloblastomas and a subset of
rhabdomyosarcomas.
CUTANEOUS SCC
Etiology and genetics Cutaneous SCC frequently presents as
a ¢rm, pink papule or nodule, with a conspicuous hyperkeratotic
surface. Although they represent only about 20% of
nonmelanoma skin cancers, SCC are generally more aggressive
and occasionally lethal. SCC is more frequent with higher
cumulative sunlight exposure, as cancers associated with
occupational exposures, and in immunosuppressed patients.
Hereditary syndromes uniquely associated with SCC risk have
not been described although DNA repair defects in xeroderma
pigmentosum substantially increase the risk for SCC
development. Insight into the pathogenesis of cutaneous SCC
has come from studies of the frequent precursor lesion, actinic
keratosis (AK) (Fig 3). These benign hyperproliferative-
hyperkeratotic lesions frequently have sunlight-induced clonal
p53 mutations suggesting clonal expansion from a single cell
carrying a speci¢c p53 mutation. Most frequently, these
mutations are in codon 278 or other codons of the DNA-
binding domain of p53 that contain dipyrimidine sites (Hussain
and Harris, 1998). Of particular interest is the common ¢nding of
LOH at particular chromosomal sites such as 13q, 17p, 17q, 9p, and
9q (Rehman et al, 1994). Frequently, multiple sites of allelic loss
are detected in the same lesion. As actinic keratoses progress
to SCC at an extremely low frequency, the challenge is to
determine which of these genetic lesions, if any, contributes to
premalignant progression. Analyses of SCC have also revealed
frequent LOH and p53 mutations, but a modal allelic loss or
speci¢c p53 codon strongly associated with the acquisition of a
malignant phenotype is yet to be identi¢ed (Quinn et al, 1994).
Other genetic changes have been associated with progression in
SCC, and their possible involvement in pathogenesis has been
explored in experimental studies. Mutations in the K-RAS and
Ha-RAS gene are detected in both AK and SCC, and activation
of the RAS pathway through mutation of the gene or growth
factor stimulation may be extremely common in squamous
tumors, particularly in sites with intense exposure to UV
radiation (Pierceall et al, 1991; Kreimer-Erlacher et al, 2001).
Inactivating mutations or epigenetic silencing of p16INK4a and
activation of telomerase are other pathways associated with SCC
development (Taylor et al, 1996; Sou¢r et al, 1999). Constitutive
activation of the EGF receptor (EGFR) by ampli¢cation or
expression of ligands with the formation of an autocrine loop is
a frequent ¢nding in SCC (Moghal and Sternberg, 1999).
Although these correlations have provided clues to pathways
involved in SCC pathogenesis, de¢nitive causal associations in
human SCC have not yet been con¢rmed. For this reason,
model systems utilizing human and mouse keratinocytes in
culture and animal models in vivo have been developed and
utilized to test causal relationships at the molecular, cellular, and
organism levels.
Experimental models of cutaneous SCC The induction of
squamous cell cancers on mouse skin by chemical carcinogens or
UV light has been an excellent model to study cancer
pathogenesis in general and skin cancer development in
particular. These models have shown remarkable phenotypic
homology to human SCC development and have provided
additional information on the contribution of speci¢c genetic
changes to particular stages of tumor progression. The addition
of genetically modi¢ed mice to the mix of models available has
Table IV. Experimental models for basal cell carcinoma
Exogenous inducers
Agent Species Comments
MCA Rat other skin tumors
DMBA Rat SCC4 BCC; lower DMBA doses
may increase BCC incidence
Ionizing radiation Rat other skin tumors
Dehydroretronecine Mouse BCC4 SCC, also internal tumors
Genetic models
Modi¢cation Ehancers Comments
K14-SHH ? lethal phenotype, not transplantable
LTR-SHH ? super¢cial BCC
K5-M2SMO ? impaired survival
Ptchþ / UV, IR, Arsenic other tumor types
K5-GLI1 ? other tumor types
K5-Gli2 ? exclusively BCC
Figure 3. Genetic changes associated with human cutaneous SCC.
The multistage evolution of invasive SCC is depicted schematically with
frequently associated genetic changes detailed below. Single base mutations
in early lesions frequently are characteristic of UV light-induced damage,
whereas later changes are associated with genomic instability. Increased ac-
tivity of telomerase (deletion of inhibitor) or EGFR tyrosine kinase (gene
ampli¢cation) may also result from epigenetic changes.
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further clari¢ed the speci¢c requirements for particular genes and
their downstream pathways in benign and malignant tumor
formation (Table V). Together with in vitro analysis of
keratinocytes, the biochemistry of SCC development is being
revealed.
Animal model studies indicate that heterozygous activating
Ras gene mutations are su⁄cient to induce a benign squamous
lesion, and this is coupled to constitutive activation of the
EGFR (Yuspa, 1994) (Fig 4). Activation of the keratinocyte
EGFR through transgenic targeting of TGFa to the epidermis
can also produce a benign tumor phenotype in the absence of
Ras mutations, but tumors regressed unless subjected to
continuous exposure to tumor promoters (Vassar et al, 1992;
Dominey et al, 1993; Jhappan et al, 1994). This suggests that
activation of the EGFR is not su⁄cient for autonomous tumor
formation, and alterations in other pathways are required. Under
conditions of high expression or homozygosity of a mutant Ras
gene, progression to malignancy is enhanced (Quintanilla et al,
1986; Greenhalgh and Yuspa, 1988), suggesting that the Ras
pathway can recruit additional changes required for progression.
The target cell for Ras activation in the epidermis may also
determine the tumor phenotype as transgenic targeting of
oncogenic Ras to keratinocytes committed to the di¡erentiation
program produces terminally benign tumors whereas targeting to
less di¡erentiated cells permits progression to SCC (Brown et al,
1998). In contrast, suprabasal targeting of c-Myc produces the
papilloma phenotype, possibly through reducing apoptosis,
whereas basal cell targeting of c-Myc is not oncogenic
(Pelengaris et al, 1999; Waikel et al, 2001). Deletion of the cyclin/
CDK inhibitor p21waf1, a downstream e¡ector of p53, increases
the number of benign tumors but does not in£uence the rate of
premalignant progression (Missero et al, 1996; Weinberg et al,
1999). In contrast, p53 depletion enhances malignant progression
but does not increase benign tumor formation (Kemp et al, 1993).
These results suggest that the p53 pathway involving cell cycle
inhibition through p21waf1 does not determine the risk for
malignant conversion, but another p53 regulated pathway is
critical for suppression of premalignant progression. TGFb plays
a dual role in experimental SCC development, suppressing
premalignant progression while enhancing phenotypic
progression from SCC to a spindle cell phenotype (Glick et al,
1994; Portella et al, 1998; Go et al, 1999). Members of the AP-1
transcription factor family also play a dual role in experimental
skin tumor development, where c-June is essential for papilloma
and c-Fos is essential for SCC development (Saez et al, 1995;
Young et al, 1999). Other pathways now implicated in SCC
development and progression to spindle cell tumors from
experimental studies are cyclin D1, ornithine decarboxylase,
p16ink4A, p15ink4A, and E-cadherin (Navarro et al, 1991; Cli¡ord
TableV. Experimental models for squamous cell tumor induction
Exogenous inducers
Agent Species Comments
(PAH, NA, AA) þ promoter mouse, rat predominantly papilloma
(PAH, NA, AA) repeated mouse, rat predominantly SCC
ultraviolet B mouse p53 mutations, immune suppression, SCC
ultraviolet A mouse papillomas and SCC
Gentically modi¢ed mouse models
Modi¢cation Enhancers Comments
Tg.AC (z globin-v-rasHa) promoters, drugs enhancers upregulate transgene
Tg.AC UVB p53 mutations are absent
K1-ras, K10-ras promoters predominantly papillomas
DK5-ras papillomas, KA, SCC
K6-ras promoters SCC
K1-TGFa, K14-TGFa, MT-TGFa promoters predominantly papillomas that regress
Inv-c-MycER papilloma
K1-v-fos promoters papilloma
K5-E2F1 p53 de¢ciency papilloma, SCC, BCC
K5-Igf1 promoters papilloma, SCC
K5-ErbB2 promoters papilloma, SCC
K5-SOS-F tumors inhibited by Egfr de¢ciency
K14-HPV16 FVB/N mouse strain tumors inhibited by di£uoromethylornithine
K6-ODC DMBA SCC, K-ras mutations
XP mutant models (A, C, D) initiation/promotion/UVR enhanced sensitivity
Egfr null mutant v-rasHa reduced tumor size
p53 null mutant DMBA/TPA enhanced malignant conversion
p21waf1 null mutant DMBA/TPA enhanced papilloma formation
c-fos null mutant cross with Tg.AC papilloma but no SCC
K14-PKCe DMBA/TPA enhanced SCC, metastases
K14-PKCd DMBA/TPA reduced papilloma development
Figure 4. Genetic changes associated with chemically induced
mouse cutaneous SCC.The multistage evolution of anaplastic or spindle
cell tumors in this model is highly ordered both temporally and geneti-
cally. Rasmutations are characteristic of chemical mutagens used to initiate
tumor formation. Early upregulation of cyclin D1 and later up-regulation
of TGFa1 occur through epigenetic mechanisms and appear to be impor-
tant components of carcinogenesis.
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et al, 1995; Linardopoulos et al, 1995; Robles et al, 1998). These
pathways are frequently altered in human SCC, but their
contribution to pathogenesis remains to be proven by studies that
directly transform human keratinocytes in an in vivo setting.
Mouse models promise to reveal another essential aspect of skin
cancer pathogenesis, that of individual susceptibility. Inbred mouse
strains di¡er in susceptibility to particular exposures by several
orders of magnitude (DiGiovanni et al, 1992). Carcinogenesis
studies on cultured mouse keratinocytes derived from di¡erent
background strains or on skin from speci¢c strains grafted to
nude mice indicate that sensitivity is determined by the target
tissue rather than systemically (Yuspa and Morgan, 1981; Yuspa
et al, 1982; Glick et al, 1999). Tumor induction on F1 hybrid
backcrosses between sensitive and resistant strains followed by
genome scans using microsatellite markers has revealed that
determinants for susceptibility or resistance are multigenic and
distinct for benign tumor formation or premalignant progression
and malignant conversion (Nagase et al, 1995; Mock et al, 1998).
Analysis of congenic strains and other approaches indicate that
speci¢c loci are epistatic, and the interactions are speci¢c for
benign or malignant tumor formation (Nagase et al, 2001).
Genetic loci also determine the survival potential for tumor-
bearing animals (Nagase et al, 1999). As the speci¢c genes are
identi¢ed for these determinants, syntenic sites in the human
genome that determine skin cancer susceptibility may be revealed.
CONCLUSION
The rapidly accumulating genetic details of cutaneous cancer
pathogenesis combined with the illumination of interacting sig-
naling pathways downstream from the genes involved provides
an opportunity to model the biochemistry of cutaneous tumors,
a scheme that must ultimately be understood for rational therapy
or medical intervention. Currently any biochemical model would
almost certainly be incomplete. Alternatively, a general biologic
scheme that may ¢t the multistage development of both melano-
ma and squamous cell skin cancers might be constructed with
current information. The scheme has value as an organizational
foundation to focus on emerging understanding of the biochem-
istry of the individual biologic processes and to test the biochem-
ical principles in cutaneous cancer models. Such a scheme (Fig 5)
assigns aberrations in control of proliferation, normal di¡erentia-
tion, apoptosis or senescence, or developmental processes (in the
case of some hereditary syndromes) as early events. As a conse-
quence of these changes or coupled to p53 mutations, resistance
to terminal cell death produces a survival advantage for the inci-
pient cancer cells. Under selective pressure (cytotoxicity from
sunlight or environmental chemicals being the most obvious
exogenous sources), clonal expansion produces a clinically appar-
ent benign lesion (AK) or dysplastic nevus. Premalignant pro-
gression is associated with genomic instability that could be
inherent in a lesion with enhanced survival and a high prolifera-
tion rate. Nevertheless, other important changes must occur in
this growing lesion that could be modulated by the host re-
sponse. An in£ammatory reaction could deposit cytokines in the
lesional environment as well as mutagenic reactive oxygen or ni-
trogen species (Smith et al, 1998; Hussain et al, 2000; Fitzpatrick,
2001). Angiogenesis and immune surveillance may play opposing
roles or systemic immunosuppression may act in concert with an-
giogenesis to enhance progression (Prehn and Prehn, 1996;
Smith-McCune et al, 1997). Many cell generations may pass as
the positive and negative in£uences of the organismal response
interact with the endogenous activities of the neoplastic lesion.
Subsequent clones evolve and subclones from these as further sur-
vival advantage is acquired and selected. Alternatively, lethal ge-
netic aberrations may arise and account for the spontaneous
regression of some AK or melanotic lesions. The tumor environ-
ment evolves concomitant with clonal selection, altering the in-
teractions of stromal, epithelial, and in£ammatory components
and the tumor matrix itself. It is this balance that ¢nally allows
for the invasive properties of tumor cells to be displayed. Thus,
we see experimental evidence for stromal and matrix determi-
nants of tumor cell behavior (Arias, 2001; Liotta and Kohn,
2001). The advantage the host has over the tumor cell is time.
The opportunity for intervention is long. Our goal, in addition
to education and lifestyle change, should be reduction in mortal-
ity, morbidity, and deformity.The knowledge to achieve this goal
is rapidly evolving. Cutaneous cancer intervention and therapy is
ideally suited to showcase the opportunities for rational ap-
proaches to cancer control and cancer cure.
Due to the breadth of this review, we apologize for the unavoidable exclusion of refer-
ences to work done by many outstanding investigators working in these areas.We wish
to acknowledge the contribution of Dr. Luowei Li to the construction of the ¢gures and
Ms. Bettie Sugar for outstanding editorial assistance.
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